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Abstract
Background: Topiramate might be effective in the treatment of posttraumatic stress disorder
(PTSD) because of its antikindling effect and its action in both inhibitory and excitatory
neurotransmitters. Open-label studies and few controlled trials have suggested that this
anticonvulsant may have therapeutic potential in PTSD. This 12-week randomized, double-blind,
placebo-controlled clinical trial will compare the efficacy of topiramate with placebo and study the
tolerability of topiramate in the treatment of PTSD.
Methods and design: Seventy-two adult outpatients with DSM-IV-diagnosed PTSD will be
recruited from the violence program of Federal University of São Paulo Hospital (UNIFESP). After
informed consent, screening, and a one week period of wash out, subjects will be randomized to
either placebo or topiramate for 12 weeks. The primary efficacy endpoint will be the change in the
Clinician-administered PTSD scale (CAPS) total score from baseline to the final visit at 12 weeks.
Discussion: The development of treatments for PTSD is challenging due to the complexity of the
symptoms and psychiatric comorbidities. The selective serotonin reuptake inhibitors (SSRIs) are
the mainstream treatment for PTSD, but many patients do not have a satisfactory response to
antidepressants. Although there are limited clinical studies available to assess the efficacy of
topiramate for PTSD, the findings of prior trials suggest this anticonvulsant may be promising in the
management of these patients.
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Posttraumatic stress disorder (PTSD) is the only psychiat-
ric disorder that has an etiologic component: exposure to
a traumatic event. The disorder is characterized by three
symptom clusters: reexperience of the event, avoidance/
numbing, and hyperarousal resulting from exposure to a
traumatic event[1]. Data from the National Comorbidity
Survey in United States estimated a lifetime PTSD preva-
lence rate at 7.8% (10.4% for women and 5% for men)
and to be more prevalent among women and the previ-
ously married. The trauma most likely to be associated
with development of PTSD among men (69%) and
women (45.9%) alike was rape. Survival analyses demon-
strated that PTSD failed to remit in more than one third of
persons even after several years of the occurrence of the
traumatic event, demonstrating that PTSD tends to be a
chronic disorder [2].
Furthermore, PTSD has a high comorbidity with other
psychiatric conditions such as substance abuse/depend-
ence, anxiety disorders, and major depressive disorder
causing a worsening prognosis [2].
The development of treatments for PTSD is challenging
due to the complexity of the symptoms and psychiatric
comorbidities. Psychotherapy and pharmacotherapy are
the two main classes of PTSD treatment. In the Cochrane
systematic review, Bisson and Andrew [3] evaluated the
efficacy of five categories of psychotherapeutic interven-
tions: trauma-focused cognitive- behavioral therapy/
exposure therapy (TFCBT), stress management, other ther-
apies (supportive therapy, nondirective counseling, psy-
chodynamic therapy, and hypnotherapy), group cognitive
behavioral therapy and eye movement desensitization
and reprocessing (EMDR). The authors analysed thirty-
three studies and concluded that individual TFCBT, stress
management, group TFCBT, and EMDR were more effec-
tive than wait list and other therapies. Bradley et al [4]
conducted a multidimensional meta-analysis of psycho-
therapy studies published between 1980 and 2003. The
meta-analysis included twenty six studies and reviewed
exposure therapy, cognitive behavioral therapy (CBT),
exposure plus CBT, EMDR and others. The authors found
that exposure therapies, other cognitive behavior therapy
approaches, and EMDR are efficacious in reducing PTSD,
but found no significant differences between the various
CBT modalities and between CBT and EMDR. Several
review of psychotherapy have been published demon-
strating that cognitive-behavioural and similar psycho-
therapies are effective in the treatment of PTSD.
The National Institute for Clinical Excellence (NICE) [5]
recommended trauma focused psychological therapy as a
routine first-line treatment for adults in preference to
pharmacotherapy. In cases that drug treatment is
required, paroxetine and mirtazapine were approved for
general use, and amitriptyline and phenelzine for use only
by mental health specialists. Although controlled trials
with paroxetine did not show significant benefits on the
main outcome variables, this is the only drug approved
for PTSD in UK.
In a recently published systematic review, Stein et al [6]
evaluated thirty five short term randomized controlled
medication trials for PTSD (4597 participants). In thirteen
trials, response to medication occurred in 59.1% of
patients (644 participants), while response to placebo was
seen in 38.5% of patients (628 participants). Significant
reductions in symptom severity were observed for patients
who received medications in seventeen trials. The mean
total CAPS score for the medication group was 5.76 points
lower than that for the placebo group (95% CI – 8.16 to -
3.36 and 2507 participants). Evidence of treatment effi-
cacy was most convincing for the SSRIs. Furthermore,
medication was superior to placebo in reducing the sever-
ity of the three symptom clusters of PTSD, as well as alle-
viating the symptoms of depression, and in improving the
quality of life measures. The current evidence base of ran-
domized clinical trials is unable to demonstrate superior
efficacy or acceptability for any particular medication
class.
Nevertheless, the bulk of evidence for the efficacy of med-
ication has been with the SSRIs and supports expert con-
sensus guidelines that these medications constitute the
first-line medication choice in PTSD.
The American Psychiatric Association [7] practice guide-
lines rated the SSRIs as first-line pharmacotherapy, with
sertraline and paroxetine being US Food and Drug
Administration approved for PTSD. The authors did not
find efficacious pharmacological intervention to recom-
mend in preventing the development of acute stress disor-
der or PTSD. The tricyclics antidepressants and
monoamine oxidase inhibitors may also be beneficial
(recommended with moderate clinical confidence) and
the benzodiazepines, anticonvulsants, antipsychotics and
adrenergic inhibitors may be recommended on the basis
of individual circumstances. Trials of atypical antipsychot-
ics olanzapine and risperidone found some evidence in
terms of efficacy for PTSD with psychotic symptoms.
Olanzapine, a second-generation antipsychotic agent,
when prescribed to augment ongoing sertraline treatment,
was shown to produce improvement in PTSD, depressive,
and sleep-related symptoms in Vietnam veterans [8].
Open-label studies of adjunctive olanzapine have demon-
strated symptom reduction in veterans with PTSD [9]. A
small controlled study of risperidone in chronic combat
related PTSD and comorbid psychotic symptoms demon-
strated that reexperiencing and global psychotic symp-Page 2 of 7
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mainstream treatment for PTSD, many patients do not
have a satisfactory response to these antidepressants. The
development of pharmacological treatments for PTSD is
challenging due to the heterogeneity of symptoms.
Recently, anticonvulsants have been evaluated for their
potential efficacy for the treatment of PTSD. Open and
randomized trials of carbamazepine [11], valproic acid
[12,13], and lamotrigine [14] suggested that these agents
may be efficacious in PTSD treatment.
The hypotheses on the etiology of PTSD have suggested
that after exposure to traumatic events; the limbic nuclei
may become kindled or sensitized, resulting in increased
susceptibility to physiologic arousal [15,16]. The implica-
tion of the limbic kindling-like phenomenon in the
pathophysiology of PTSD has stimulated clinical research
in antiepileptic drugs in the treatment of PTSD.
Topiramate is an anticonvulsant with inhibitory activity
in animal kindling models and with multiple mecha-
nisms of action: inhibition of carbonic anhydrase, block-
ade of Na+ channels, inhibition of some high-voltage-
activated Ca2+, negative modulating effect on the kainate/
AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propri-
onic acid) subtype of glutamate receptors, ability to mod-
ulate NMDA (Nmethyl-D-aspartate) glutamate receptor
and enhancement of GABAergic activity at GABA2 recep-
tors [17,18].
The blockage or the stabilization of the AMPA (α-amino-
3-hydroxy-5 methyl-4 isoxazole propionic acid) receptor
may be a possible mechanism responsible for the increase
in the threshold for flashbacks and nightmares that may
explain the treatment response to topiramate in PTSD
[19]. Several animal model studies show that AMPA
antagonists attenuate acoustic startle response when
administered into the amygdala. For instance, Khan and
Liberzon [20] demonstrated that topiramate reduced sig-
nificantly the acoustic startle response in rats after a single
prolonged stress episode.
Glutamatergic neurons play a role in the neuronal plastic-
ity associated with longterm potentiating in adaptation to
stress [21]. Glutamate is the primary excitatory neuro-
transmitter in the central nervous system. Glutamate
NMDA (N-methyl D-aspartate) receptors have been
implicated in reconsolidation, and extinction of memo-
ries. The reconsolidation of spatial and contextual fear
memory and odor reward association is impaired by
NMDA antagonists [22,23]. Lee et al [24] demonstrated
that the NMDA receptor antagonist (+)-5-methyl-10,11-
dihydro-SHdibenzo [a, d] cyclohepten-5,10-imine
maleate (MK-801) blocked and the agonist D-cycloserine
(DCS) potentiated extinction of fear memory when they
were administered before a long extinction training ses-
sion whereas MK-801 impaired and DCS increased recon-
solidation of memory when they were administered
before brief memory reactivation session.
Although much of the research associate the glutamatergic
systems with learning and memory; the GABAergic (γ-
aminobutyric acid) system in the basolateral amygdala, is
also involved in the acquisition and extinction of fear
memories [25]. Reduced GABA function is involved in the
formation of fear memories and the development of anx-
iety disorder. Stork et al [26] found that conditioned fear
in mice is associated with a reduction of extracellular
GABA levels in the amygdala indicative of a reduced
GABA release and/or increased GABA uptake from the
extracellular space.
Clinical studies with topiramate suggest that it is effective
as monotherapy or adjunctive therapy in PTSD. Two
open-label studies demonstrated topiramate to be effec-
tive and to have a rapid onset of action. Berlant and van
Kammen [27] have reported that topiramate decreased
nightmares in 79% and flashbacks in 86% of civilian
patients with chronic PTSD with improvement of night-
mares in 50% and of intrusions in 54% of patients with
these symptoms. A partial response was reported for 95%
of patients at a dosage of 75 mg/day or less and in 91% of
full responders at a dosage of 100 mg/day or less. The
nonhallucinatory subgroup achieved a higher response
rate (89%). In a prospective open-label study, Berlant [28]
treated thirty three civilians with chronic PTSD, with
topiramate as monotherapy or augmentation therapy.
The PTSD Checklist-Civilian Version (PCL-C) total symp-
toms declined by 49% at 4th week, with similar subscale
reductions for reexperiencing, avoidance/numbing, and
hyperarousal symptoms. Topiramate suppressed night-
mares in 79% and decreased symptoms of intrusions in
94% in those patients with these symptoms. There is only
one double-blind, placebo- controlled study of topiram-
ate as a monotherapy in PTSD. Tucker [29] conducted a
12-week, double-blind, placebo-controlled evaluation of
topiramate as a monotherapy in thirty eight civilian PTSD
patients. Patients in the topiramate group exhibited signif-
icant reductions in reexperiencing symptoms (CAPS clus-
ter B: topiramate = 74.9%; placebo = 50.2%; p = .038) and
reductions approaching statistical significance, based on a
nominal p value, were noted in mean total Clinical Glo-
bal Impressions-Improvement Scale scores (topiramate =
1.9 ± 1.2; placebo = 2.6 ± 1.1; p = .055). Although there
was a reduction in total Clinician-Administered PTSD
Scale (CAPS) score from baseline (topiramate = -52.7; pla-
cebo = -42.0), the difference was not statistically signifi-
cant (p = .232). But not all studies found positive results,
Lindley [30] in a double-blind, placebo-controlled study
using topiramate as an augmentation therapy in fortyPage 3 of 7
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ment effects versus placebo. However, there was a high
dropout rate from the study with 11 (55%) topiramate
and 5 (25%) placebo subjects not completing the seven
week treatment, with 40% of topiramate and 10% of pla-
cebo dropping because of adverse effects. Patients in the
topiramate group that completed the study, had a signifi-
cant improvement in the reexperiencing subscale of the
CAPS suggesting efficacy for the patients that continued
the medication.
Extensive efforts have been made to establish guidelines
based in evidence for PTSD treatment, however there is
still no specific drug proved efficacious. Although there
are limited clinical studies with topiramate in the treat-
ment of PTSD, the findings of prior topiramate studies
suggest that this anticonvulsant may be promising in the
management of patients with PTSD.
Aims of the Study
1) To compare the efficacy of topiramate with placebo in
the treatment of PTSD. Clinical response will be consid-
ered when there are a 20% reduction on CAPS scale scores
from baseline and remission when CAPS score is less than
19.
2) To study the tolerability of topiramate in the treatment
of PTSD, through the dropout rate in each group.
Research Goals
The trial will compare the efficacy of topiramate with pla-
cebo in the treatment of PTSD, and will study its tolerabil-
ity through the drop out rate in each group. The primary
hypothesis is that topiramate will be superior to placebo
in the treatment of PTSD. Secondary research goals
includes studying the efficacy of topiramate in social
adjustment, functioning and quality of life. Additionally,
evaluating treatment adhesion, and studying the efficacy
of topiramate in depressive symptoms.
Materials and methods
Subjects
All elegible patients admitted at the outpatient clinic from
the violence program of Federal University of São Paulo
Hospital (UNIFESP) who read and signed a consent
inform approved by the UNIFESP Institutional Review
Board (IRB) will enter the study. A pre-request to be
admitted at this program is having passed through a stres-
sor event which imposed a risk on subjects' physical and/
or psychological integrity (DSM-IV criterion A for PTSD
diagnostic). Patients looked for an appointment at the
program spontaneously, or through health worker recom-
mendation or were called by phone or by mail from a list
of subjects which had a PTSD diagnostic after a CIDI sub-
mission by trained raters on the Sao Paulo epidemiologi-
cal catchment area study. This was an epidemiological
survey of a random sample of 3000 participants living in
the city of Sao Paulo to assess the relationship between
exposure to violence and the prevalence of PTSD and
common mental disorders.
All patients will be administered the Structured Clinical
Interviews for DSM-IV Axis I and Axis II (SCID-I and
SCID-II, respectively) by a trained psychiatrist [31,32].
Patients will be eligible if they meet the inclusion criteria:
1) DSM-IV criteria for a diagnosis of PTSD [1], 2) both
gender, aged between 18 to 60 years of age. 3) Women of
childbearing potential have to be practicing reliable con-
traception and cannot be pregnant or breast-feeding dur-
ing the course of the study. The exclusion criteria will be:
1) lifetime history of bipolar, psychotic, borderline per-
sonality disorder; substance dependence or abuse (exclud-
ing nicotine and caffeine) in the previous 6 months; 2)
serious or unstable concurrent illness; history of nephro-
lithiasis, 3) use of psychotropic medications for the previ-
ous 2 weeks (6 weeks for fluoxetine); 4) body mass index
below 20; 5) current suicidal ideation or psychotic symp-
toms will be excluded from the study.
Measures
• The Structured Clinical Interview for DSM-IV-Axis I and II
(SCID-I and II) [31,32]: is a semi-structured interview that
allows for the diagnosis of Axis I and II disorders, respec-
tively, according to DSM-IV criteria [1].
• The Clinician-Administered PTSD Scale (CAPS) [33]: is a
structured interview developed to diagnose PTSD and rate
its severity. It is comprised of 30-items to assess PTSD-
related symptom frequency and severity. Scores range
from 0 to 136, with scores classified as follows: subclini-
cal, from 0 to 19; mild, from 20 to 39; moderate, from 40
to 59; severe, from 60 to 79; extreme, 80 and above.
• The Beck Depression Inventory (BDI) [34]: is a 21-item
self-report inventory designed to measure the severity of
depression. Scores range from 0 to 63, with depression
classified as minimal when scores range from 0 to 11,
mild from 12 to 19, moderate from 20 to 35, and severe
from 36 to 63.
• MOS 36-Item Short-Form Health Survey (SF-36) [35]: is a
scale to measure mental and physical health concepts. It is
a 36-item self-report instrument. The SF- 36 measures
social functioning correlated to clinical conditions. As
higher is the score, better is the quality of life. The instru-
ment gave a global score, as specific areas scores: func-
tional capacity, physical aspects, pain, general health
condition, vitality, social aspects and emotional aspects,
and mental health.Page 4 of 7
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ranging from 1 to 5 from normal to severely misadjusted.
Used to evaluate social adjustment, normal score is
around 1.56 (+/- .36).
• Global Assessment of Functioning (GAF) Scale [38]: is a sin-
gle-item rating scale for evaluation the overall patient
functioning during a specified period on a continuum
from psychological or psychiatric sickness to health. The
scale value ranges from 1 (hypothetically sickest person)
to 100 (hypothetically healthiest person), divided into 10
equal intervals. A modified version of the Global Assess-
ment Scale (GAS) was included in DSM-III as the Global
Assessment of Functioning (GAF) Scale.
• The Clinical Global Impression – Severity scale (CGI-S)
[37]: is a 7-point scale that requires the clinician to rate
the severity of the patient's illness at the time of assess-
ment, relative to the clinician's past experience with
patients who have the same diagnosis. Considering total
clinical experience, a patient is assessed on severity of
mental illness at the time of rating 1 = normal, not at all
ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately
ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
• The Clinical Global Impression – Improvement scale (CGI-I)
[38]: is a 7 point scale that requires the clinician to assess
how much the patient's illness has improved or worsened
relative to a baseline state at the beginning of the interven-
tion, and rated as: 1, very much improved; 2, much
improved; 3, minimally improved; 4, no change; 5, mini-
mally worse; 6, much worse; or 7, very much worse.
Study design
This is a 12-week randomized, double-blind, placebo-
controlled clinical trial that will be conducted at the Fed-
eral University of São Paulo Hospital (UNIFESP). The
study was approved by UNIFESP Institutional Review
Board (IRB), and will follow the Helsinky Declaration,
and the local ethical laws. Ethical Committee: 196/96
Screening Phase
After the SCID-I and II administration, eligible patients
will undergo a brief physical examination with height,
weight, heart rate and systemic blood pressure measured
and a clinical evaluation including electrocardiogram
(EKG) and laboratory blood test for complete blood
count, fasting glycemia, sodium, potassium, urea, creati-
nine, T3, T4, and TSH. Women will have a pregnancy test
done, to assure they are not pregnant. The psychiatrist
who administered the SCID, will also evaluate patients
clinical conditions and functionality through CGI-S and
GAF. The Clinician-Administered Posttraumatic Stress
Scale (CAPS)[33] will be administered to the patients by
trained raters, patients also will completed the Beck
depression inventory (BDI) [34], the medical outcomes
self-report (SF-36)[35] and the social adjustment scale
(SAS) [36].
Wash-out phase
Patients will receive placebo pills and will be re-evaluated
by the same psychiatrist one week after. Those having a
significant improvement of the symptoms (a CGI-I score
less than 3) will be excluded (avoiding premature placebo
effects).
Active treatment phase
Those patients without improvement during the placebo
trial, and do not show any laboratory and clinical condi-
tion exclusion criteria will be randomly assigned to
receive either placebo or topiramate, in a 1:1 ratio using
computer- generated code. The active and placebo pills
will be identical. All research and clinical staff will be
blinded to the randomized assignments.
Study medication will start at 25 mg/day once daily, at
night, and will be increased 25 mg weekly, as tolerated,
until complete or nearly complete efficacy is achieved or
until 200 mg/day is reached. No other psychotropic med-
ications will be allowed during the study, except for zolpi-
dem (10 mg/day), if needed, for insomnia.
Study follow-up visits will be conducted at baseline, and
weeks 1, 2, 3, 4, 6, 8, and 12.
Symptoms and side effects will be assessed, as well as
measurement of systemic blood pressure and pulse rate in
each visit by the investigator, who is blind to medication
assignment. Compliance will be assessed by counting the
amount of pills left in the bottle of medicine in each visit.
Treatment will be continued for 12 weeks (active treat-
ment phase); then drug administration will be withdrawn
gradually during 2 weeks with reductions of 25/50 mg
every three days, according to the final dosage reached.
Patients will be assessed until completing 6 months dur-
ing a follow-up period. If a patient showed a symptoma-
tology worsening during the active treatment phase (12
weeks) when receiving active drug treatment, character-
ized by a one-point decrease at CGI -I or present serious
adverse effects related to medication, he/she will be
excluded from the study.
Sample Size
The number of subjects calculated for the trial is 72, being
36 on each cell. The sample size was calculated consider-
ing a 5% probability of type I error (significance level),
and 20% for type II error (power test of 80%), on a bi-cau-
dal test. To the calculation we use an average of 60% forPage 5 of 7
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literature, and 30% of placebo response.
Statistical Analysis
All data will be analyzed by SPSS (version 13.0). The fre-
quencies of nominal variables from all patients will be
calculated. The data analysis will be conducted using a
ANOVA comparing each scale during the 2 continuous
measures from baseline and 12 weeks with a Between
Subject factor was included as independent variable
(treatment group). The confidence level that will be used
for all comparisons will be 5% (p < .05). All observed
Power as a type II error function will be presented with
minimum values of significance for each comparison.
CAPS scores from baseline and endpoint will be stratified
according severity, as nominal data they will be compared
using the chi-square test and the Fisher test when there
were cells that counted less than five or at least one cell
counted zero subjects. For missing data we will use the last
observation carried forward strategy for an intention-to-
treat analysis.
Efficacy analyses will be performed in the intent-to-treat
population of patients who received at least one dose of
topiramate. The primary efficacy endpoint will be the
change in PTSD Scale- CAPS total score from baseline to
the final visit at 12 weeks, which will be compared
between treatment groups. Missing efficacy data at 12
weeks will be imputed with the last observation carried
forward. The secondary outcomes between groups will be
comparing the Clinical Global Impressions (CGI), the
Beck Depression Inventory (BDI), the Global Assessment
of Function (GAF), and the PANAS scales. Other second-
ary analyses will include an evaluation after 24-weeks (12-
week after last patient visit with drug) data with endpoint
analyses between the treatment groups covarying for base-
line scores. On all secondary outcomes, the Bonferroni
correction will be applied for testing multiple variables.
Response will be defined as a 20% improvement in the
baseline CAPS total or positive symptom scores at 12
weeks and will be compared between treatment groups
using a chi-square test. Proportions of patients complet-
ing the 12-week double-blind study will be compared
between treatment groups using a chi-square test. Adverse
events reported by 10% of patients in each treatment
group will be compared using a chi-square test. Labora-
tory values, vital signs and physical examinations are
going to be compared from baseline and in reference to
normal ranges, and reported as normal or abnormal.
Changes in body weight (lb), body mass index (BMI; kg/
m2) at last visit in the 12-week dataset will be compared
as mean changes between treatment groups using t-tests.
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